Qureight raises $20M in Series B to expand its AI-driven imaging research platform for cardiopulmonary clinical trials.
Key Details
- 1Qureight raised $20 million in Series B funding.
- 2The company is based in the UK and focuses on lung and heart disease clinical trials.
- 3Their platform offers AI-derived quantitative imaging biomarkers and CRO services.
- 4The technology is already used by biopharmas for trials involving fibrotic lung diseases.
- 5Funds will support an AI imaging lab built around 3D deep learning for chest imaging.
- 6Qureight plans expansion into diseases like asthma, pulmonary hypertension, and drug-induced lung toxicity.
Why It Matters
Qureight's enhanced platform and new imaging lab may accelerate development and deployment of AI biomarkers for a range of lung and heart diseases. This supports more efficient clinical trials and fosters broader application of imaging AI in drug development and disease monitoring.
Source
Radiology Business
Related News
•Radiology Business
Real-World Study: Radiology AI Best in Emergency and Inpatient Settings
A commercial AI tool for intracranial aneurysm detection outperformed in inpatient and emergency settings but yielded limited benefits for outpatients in a major health system study.
•Radiology Business
Epsilon Health Launches With $28M to Build 'AI-Native' Imaging Practice
Epsilon Health has exited stealth mode, raising nearly $28M to launch an 'AI-native' radiology imaging group aimed at addressing the U.S. radiologist shortage.
•Radiology Business
Harrison.ai Restructures and Launches U.S. AI-Enabled Teleradiology Venture
Harrison.ai lays off staff amid major restructuring and launches Frontier Radiology, an AI-powered U.S. teleradiology business.